In a rheumatoid arthritis patient receiving weekly methotrexate and adalimumab (40 mg subcutaneously every two weeks) who presents with high‑grade fever and elevated blood pressure, what immediate management is recommended?

Immediate Management of High-Grade Fever and Hypertension in RA Patient on Methotrexate and Adalimumab

Immediately discontinue both methotrexate and adalimumab, obtain blood cultures, chest imaging, and tuberculosis testing, and initiate empirical broad-spectrum antibiotics while pursuing urgent infectious disease evaluation. 1

Critical First Steps: Infection Workup

This presentation represents a serious infection until proven otherwise in an immunosuppressed patient on dual immunosuppressive therapy.

Immediate Diagnostic Evaluation

• Obtain blood cultures, complete blood count, comprehensive metabolic panel, C-reactive protein, and erythrocyte sedimentation rate before initiating antibiotics 1
• Perform chest CT scan to evaluate for disseminated tuberculosis, which commonly presents as scattered pulmonary nodules and hepatosplenic lesions in patients on TNF-alpha inhibitors 1
• Order tuberculosis testing including QuantiFERON-Gold or T-SPOT.TB, recognizing that purified protein derivative may be falsely negative due to immunosuppression from methotrexate, adalimumab, and any concurrent corticosteroids 1
• Consider liver and spleen imaging if fever persists without clear source, as disseminated TB frequently involves these organs in adalimumab-treated patients 1

Critical Timing Considerations

• Disseminated tuberculosis occurs most commonly in the early stages of TNF-alpha inhibitor treatment (this patient has been on adalimumab for an appropriate duration to develop reactivation TB) 1
• Screening tests performed before initiating adalimumab may have been falsely negative if the patient was on corticosteroids or other immunosuppressants at that time 1

Antibiotic Management Strategy

Initial Empirical Coverage

• Start broad-spectrum parenteral antibiotics immediately after obtaining cultures, covering typical bacterial pathogens 1
• If fever persists beyond 7-10 days despite appropriate antibiotics and cultures remain negative, strongly consider empirical anti-tuberculosis therapy with isoniazid, rifampin, ethambutol, and pyrazinamide 1
• Do not wait for microbiological confirmation to initiate anti-TB treatment in patients with persistent fever of unknown origin on TNF-alpha inhibitors, as acid-fast bacilli cultures may take 2-6 weeks to become positive 1

Tissue Diagnosis

• Pursue liver biopsy or biopsy of other affected organs early if imaging reveals hepatosplenic lesions or other focal abnormalities, as histopathology showing necrotizing granulomas can guide treatment even when initial stains are negative 1
• Send all tissue specimens for acid-fast bacilli culture, recognizing that growth may not occur for 14+ days after biopsy 1

Blood Pressure Management

• Evaluate for secondary causes of hypertension including renal complications from methotrexate (check creatinine, urinalysis) 2
• Assess for sepsis-related hemodynamic changes which may initially present with hypertension before progressing to hypotension
• Initiate standard antihypertensive therapy if blood pressure remains elevated after addressing acute infection, but recognize that fever and systemic inflammation may be contributing factors

Medication Discontinuation Rationale

Why Stop Both Drugs Immediately

• TNF-alpha inhibitors increase tuberculosis risk 5-fold, with most cases representing reactivation of latent TB presenting as disseminated disease 1
• Methotrexate causes immunosuppression that compounds infection risk and can cause hepatotoxicity, bone marrow suppression, and renal toxicity—all of which complicate management of serious infections 2
• Adalimumab has a half-life of approximately 2 weeks, so immunosuppressive effects will persist for some time after discontinuation 3

Monitoring During Drug Discontinuation

• Check complete blood count every 3-7 days to monitor for methotrexate-related bone marrow suppression (leukopenia, thrombocytopenia, pancytopenia) 2
• Monitor liver function tests as methotrexate hepatotoxicity may manifest or worsen during acute illness 2
• Assess renal function closely as methotrexate is renally cleared and acute kidney injury will increase toxicity risk 2

Common Pitfalls to Avoid

• Do not continue immunosuppressive therapy while pursuing infection workup—the risk of progressive infection far outweighs the risk of RA flare 1
• Do not rely solely on standard TB screening tests (PPD, QuantiFERON) to rule out tuberculosis, as these may be falsely negative in immunosuppressed patients 1
• Do not delay empirical anti-TB therapy if fever persists beyond 7-10 days without alternative explanation, even if initial TB tests are negative 1
• Do not assume negative initial tissue stains exclude tuberculosis—cultures may become positive weeks later, and histopathology showing granulomas should prompt empirical treatment 1

When to Resume RA Therapy

• Only restart methotrexate and adalimumab after infection has been definitively treated or excluded, fever has resolved for at least 1-2 weeks, and inflammatory markers have normalized
• If tuberculosis is confirmed, complete at least 2 months of intensive anti-TB therapy before considering resumption of immunosuppressive therapy, and only in consultation with infectious disease specialists 1
• Consider switching to a different DMARD strategy if tuberculosis is confirmed, as risk of reactivation remains elevated with TNF-alpha inhibitors even after TB treatment 1